Session

News in LUTS pharmacotherapy

Poster Session 40

  • Location:
    Room Milan, North Hall (Level 1)
  • Chairs:
     J.C. Nickel, Kingston (CA)
     P. Nyirády, Budapest (HU)
     N. Thiruchelvam, Cambridge (GB)
  • Aims and objectives of this session

    The objectives of this session is to understand how new pharmacologic research will impact on our understanding of LUTS and learn to use this knowledge to improve our management of storage and voiding LUTS associated with benign prostatic hyperplasia, overactive bladder and other causes of LUTS.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 531
Impact of 5-alpha reductase inhibitors for treatment of benign prostatic hyperplasia on erectile dysfunction, treated depression, gynecomastia, and breast cancer: A real world 20 year observational study

By: Hagberg K.W.2, Divan H.A.3, Persson R.2, Fang S.C.3, Jick S.S.2, Nickel J.C.1

Institutes: 1Queen’s University, Dept. of Urology, Kingston, Canada, 2Boston University School of Public Health, Boston Collaborative Drug Surveillance Program, Lexington, United States of America, 3New England Research Institutes, NERI, Watertown, United States of America

532
Phosphodiesterase inhibitors for BPH-LUTS: Is the benefit worth it?

By: Pattanaik S.1, Mavuduru R.2, Panda A.3, Mathew J.4, Aggarwal M.5, Singh S.2, Mandal A.2

Institutes: 1Postgraduate Institute of Medical Education and Research, Dept. of Pharmacology, Chandigarh, India, 2Postgraduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India, 3CMC, Dept. of Urology, Vellore, India, 4Postgraduate Institute of Medical Education and Research, Dept. of Pediatrics, Chandigarh, India, 5NMC Specialty Hospital, Dept. of Urology, Abudhabi, United Arab Emirates

* 533
Antimuscarinic use in the elderly: A poisoned apple?

By: Meyer C.1, Pucheril D.2, Karabon P.2, Gild P.1, Von Landenberg N.1, Atiemo H.2, Menon M.2, Chughtai B.3, Fisch M.4, Chun F.4, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 3Weil Cornell Medical College/New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, 4University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

534
A 52-week randomized comparative study of a triple therapy (tamsulosin, dutasteride, and imidafenacin) versus a dual therapy (tamsulosin and dutasteride) in benign prostatic hyperplasia patients with overactive bladder (DIrecT Study)

By: Yamanishi T.1, Asakura H.2, Seki N.3, Tokunaga S.4

Institutes: 1Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, 2Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, 3Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, 4Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

535
Comparison between tadalafil 5 mg vs. Serenoa repens/selenium/lycopene for the treatment of benign prostatic lower urinary tract symptoms secondary to benign prostatic hyperplasia. A phase IV, randomized, multicenter, non-inferiority clinical study. SPRITE study

By: Morgia G.1, Vespasiani G.2, Reale G.1, Di Mauro M.1, Pareo R.3, Voce S.4, Madonia M.5, Fedelini P.6, Veneziano P.7, Carini M.8, Salvia G.9, Santaniello F.10, Ginepri A.11, Bitelli M.12, Terrone C.13, Gentile M.14, Giannantoni A.15, Blefari F.16, Beatrici V.17, Polledro P.18, La Rosa P.19, Arnone S.20, Santelli G.21, Russo G.I.1

Institutes: 1University of Catania, Urology Section, Dept. of Surgery, Catania, Italy, 2University of Tor Vergata, Dept. of Urology, Rome, Italy, 3Hospital Nuovo Regina Margherita Roma, Dept. of Urology, Rome, Italy, 4Ravenna Hospital, Dept. of Urology, Ravenna, Italy, 5University of Sassari, Dept. of Urology, Sassari, Italy, 6Cardarelli Hospital, Dept. of Urology, Naples, Italy, 7Riuniti Hospital, Dept. of Urology, Reggio Calabria, Italy, 8University of Firenze, Dept. of Urology, Florence, Italy, 9ASP Acireale, Dept. of Urology, Acireale, Italy, 10Riuniti Hospital, Dept. of Urology, Ancona, Italy, 11Figlie Di San Camillo Hospital, Dept. of Urology, Rome, Italy, 12Frascati Hospital, Dept. of Urology, Frascati, Italy, 13University of Piemonte Orientale, Dept. of Urology, Novara, Italy, 14Avellino Hospital, Dept. of Urology, Avellino, Italy, 15University of Perugia, Dept. of Urology, Perugia, Italy, 16Hospital of Prato, Dept. of Urology, Prato, Italy, 17S. Croce Hospital, Dept. of Urology, Ancona, Italy, 18SS. Annunziata Di Savigliano Hospital, Dept. of Urology, Cuneo, Italy, 19Garibaldi Hospital, Dept. of Urology, Catania, Italy, 20Lugo of Romagna Hospital, Dept. of Urology, Ravenna, Italy, 21Lucca Hospital, Dept. of Urology, Lucca, Italy

536
A randomized, open-label, multicenter study evaluating efficacy of switch from dutasteride to tadalafil in benign prostatic hyperplasia patient with lower urinary tract symptoms (D-to-T trial)

By: Matsumoto T.1, Hatakeyama S.1, Yoshikawa K.2, Fukui K.3, Yanagisawa T.4, Kawaguchi T.5, Imai A.1, Yoneyama T.1, Hashimoto Y.1, Koie T.1, Saito H.6, Yamaya K.6, Funyu T.6, Ohyama C.1

Institutes: 1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Mutsu General Hospital, Dept. Of Urology, Mutsu, Japan, 3Fukui Urology Clinic, Dept. of Urology, Aomori, Japan, 4Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 5Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, 6Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

538
Impact of Vesomni™ on quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia in routine clinical practice: Interim results from the EUROPA study

By: Rees J.1, Arbe E.7, Rosa Arias J.2, Skoumal R.3, Walters C.4, Yavuz Y.5, De Wachter S.6

Institutes: 1Tyntesfield Medical Group, Brockway Medical Centre, Nailsea, United Kingdom, 2Hospital “Santiago Apóstol”, Dept. of Urology, Miranda De Ebro, Spain, 3Urocentrum Brno, Dept. of Urology, Brno, Czech Republic, 4Astellas Pharma Europe Ltd, Medical and Clinical Operations, Chertsey, United Kingdom, 5Astellas Pharma Global Development, Dept. of Data Sciences, Leiden, The Netherlands, 6University Hospital Antwerpen, University Antwerpen, Dept. of Urology, Edegem, Belgium, 7Astellas Pharma Europe Ltd, Dept. of Medical Affairs, Chertsey, United Kingdom

539
Post-operative continuous use of antimuscarinics in BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study

By: Huang E.Y.-H., Chung H.-J., Lin C.-C., Peng R.-S., Chang Y.-H., Lin A.T.-L., Chen K.-K.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

540
A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms

By: Cho S.1, Hoon C.1, Park J.Y.1, Bae J.H.1, Lee K.W.2, Yoo T.K.3, Sin D.G.4, Kim S.W.5, Kim Y.H.2

Institutes: 1Korea University Anam Hospital, Dept. of Urology, Ansan, South Korea, 2Bucheon Hospital, Soonchunhyang University, Dept. of Urology, Bucheon, South Korea, 3Ulji University Nowon Hospital, Dept. of Urology, Seoul, South Korea, 4Busan University Hospital, Dept. of Urology, Busan, South Korea, 5Seoul University Hospital, Dept. of Urology, Seoul, South Korea

541
Testosterone therapy (TTh) improves urinary function and reduces major adverse cardiovascular events (MACE) in hypogonadal men with type 2 diabetes (T2DM) treated up to 8 years in comparison to an untreated control group

By: Haider A.1, Haider K.1, Doros G.2, Traish A.3

Institutes: 1Private Urology Practice, Dept. of Urology, Bremerhaven, Germany, 2Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, 3Boston University School of Medicine, Dept. of Urology and Biochemistry, Boston, United States of America

542
The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia

By: Murtola T.1, Nygård L.2, Talala K.3, Taari K.4, Tammela T.1, Auvinen A.5

Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, 4Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 5University of Tampere, School of Health Sciences, Tampere, Finland

543
The effect of statins on the risk of receiving transurethral resection of prostate in the outpatients of genitourinary clinic - a study by applying nation-wide population based database

By: Lin C-C.1, Chung H.J.1, Lin A.T.L.1, Huang Y.H.1, Chen T.Z.2

Institutes: 1Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, 2Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei, Taiwan

544
The comparison in the efficacy of the two combination therapies with an anticholinergic agent and an α1-blocker versus a β3-adrenoceptor agonist and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective trial using a urodynamic study

By: Matsukawa Y., Matsuo K., Majima T., Narita H., Kato M., Yamamoto T., Gotoh M.

Institutes: Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan